Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Affordable Medicines | Specialty | Av KARE | Total |
|---|---|---|---|---|
| Balance as of December 31, 2024 | $161,659 | $366,312 | $69,465 | $597,436 |
| Currency translation | (1,966) | — | — | (1,966) |
| Balance as of December 31, 2025 | 159,693 | 366,312 | 69,465 | 595,470 |
| Currency translation | (1,971) | — | — | (1,971) |
| Balance as of June 30, 2026 | $157,722 | $366,312 | $69,465 | $593,499 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — goodwill?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — goodwill of $69.47M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s avkare — goodwill changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s avkare — goodwill decreased by 0.0% year-over-year, from $69.47M to $69.47M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — goodwill?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — goodwill has grown at a -0.1% compound annual growth rate (CAGR), from $279.5M to $277.86M.
- What does avkare — goodwill mean?
- Reflects the intangible asset value recorded when the AvKARE segment was acquired for a price exceeding the fair market value of its net identifiable assets. It represents the premium paid for brand reputation, customer relationships, and expected future synergies, subject to periodic impairment testing.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude